Modeling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development

Journal of Alzheimer's Disease

Volumn 62, Issue 3, 2018, Pages 1287-1303

  Wischik, Claude M ^a,b   Schelter, Björn O ^a,c   Wischik, Damon J ^a,d   Storey, John M D ^a,c   Harrington, Charles R ^a,b  

^a TAURX THERAPEUTICS LTD   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; Clinical trials; Paired helical filaments; Prion like processing; Protein aggregation inhibitors; Tau protein

Indexed keywords

TAU PROTEIN; PRION PROTEIN;

ALZHEIMER DISEASE; CLINICAL EFFECTIVENESS; DRUG DEVELOPMENT; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); METABOLISM; PROCEDURES; PROTEINOSIS;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DEVELOPMENT; HUMANS; PRION PROTEINS; PROTEIN AGGREGATION, PATHOLOGICAL; TAU PROTEINS;

EID: 85044359810     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170727     Document Type: Review

References (83)

1. Wischik CM, Lai RYK, Harrington CR (1997) Modelling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development. In Brain Microtubule Associated Proteins: Modifications in Disease, Avila J, Brandt R, Kosik KS, eds. Harwood Academic Publishers, Amsterdam, pp. 185-241.
2. Braak H, Del Tredici K (2016) Potential pathways of abnormal tau and α-synuclein dissemination in sporadic Alzheimer's and Parkinson's diseases. Cold Spring Harbor Persp Biol 8, a023630.
3. Dunning CJR, Reyes JF, Steiner JA, Brundin P (2012) Can Parkinson's disease pathology be propagated from one neuron to another? Prog Neurobiol 97, 205-219.
4. Goedert M, Masuda-Suzukake M, Falcon B (2017) Like prions: The propagation of aggregated tau and α-synuclein in neurodegeneration. Brain 140, 266-278.
5. Hasegawa M, Nonaka T, Masuda-Suzukake M (2017) Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders. Pharmacol Ther 172, 22-33.
6. Kaufman SK, Sanders DW, Thomas TL, Ruchinskas AJ, Vaquer-Alicea J, Sharma AM, Miller TM, Diamond MI (2016) Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo. Neuron 92, 796-812.
7. Lai RYK, Gertz H-J, Wischik DJ, Xuereb JH, Mukaetova-Ladinska EB, Harrington CR, Edwards PC, Mena R, Paykel ES, Brayne C, Huppert FA, Roth M, Wischik CM (1995) Examination of phosphorylated tau protein as a PHFprecursor at early stage Alzheimer's disease. Neurobiol Aging 16, 433-445.
8. Wischik CM, Novak M, Thøgersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85, 4506-4510.
9. Wischik CM, Crowther RA, Stewart M, Roth M (1985) Subunit structure of paired helical filaments in Alzheimer's disease. J Cell Biol 100, 1905-1912.
10. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA (1988) Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A 85, 4884-4888.
11. Anderton BH, Breinburg D, Downes MJ, Green PJ, Tomlinson BE, Ulrich J, Wood JN, Kahn J (1982) Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. Nature 298, 84-86.
12. Brion J-P, Passareiro H, Nunez J, Flament-Durand J (1985) Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol (Brux) 95, 229-235.
13. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung Y-C, Zaida MS, Wisniewski HM (1986) Microtubule associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261, 6084-6089.
14. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917.
15. Ihara Y, Nukina N, Miura R, Ogawara M (1986) Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 99, 1807-1810.
16. Masters C, Simms G, Weinman N, Multhaup G, McDonald B, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82, 4245-4249.
17. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K (1985) Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 4, 2757-2763.
18. Mori H, Kondo J, Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235, 1641-1644.
19. Perry G, Friedman R, Shaw G, Chau V (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A 84, 3033-3036.
20. Yen S-H, Dickson DW, Butler M, Shelanski ML (1987) Alzheimer's neurofibrillary tangles contain unique epitopes in common with the heat-stable microtubule-associated proteins tau and MAP2. Am J Pathol 126, 81-91.
21. Yen S-H, Gaskin F, Fu SM (1983) Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class. Am J Pathol 113, 373-381.
22. Wischik CM, Edwards PC, Lai RYK, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA 93, 11213-11218.
23. Rickard JE, Horsley D, Wischik CM, Harrington CR (2016) Assays for the screening and characterization of tau aggregation inhibitors. In Tau protein: Methods and Protocols, Smet-Nocca C, ed. Springer, New York, pp. 129-140.
24. Novak M, Kabat J, Wischik CM (1993) Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12, 365-370.
25. Harrington CR, Storey JMD, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM (2015) Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggregation inhibitors for treatment of Alzheimer's disease. J Biol Chem 290, 10862-10875.
26. Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, Goatman K, Goatman EA, Deiana S, Close SP, Zabke C, Stamer K, Dietze S, Schwab K, Storey JMD, Harrington CR, Wischik CM, Theuring F, Riedel G (2015) Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol 26, 353-368.
27. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
28. Mena R, Edwards P, Pérez-Olvera O, Wischik CM (1995) Monitoring pathological assembly of tau and β-amyloid proteins in Alzheimer's disease. Acta Neuropathol 89, 50-56.
29. Caputo CB, Sobel IRE, Sygowski LA, Lampe RA, Spreen RC (1993) The influence of amino acid sequence on the fibrillogenicity and amyloidogenicity of the carboxy-terminus of β-amyloid precursor protein. Arch Biochem Biophys 306, 321-330.
30. Bondareff W, Harrington C, Wischik CM, Hauser DL, Roth M (1994) Immunohistochemical staging of neurofibrillary degeneration in Alzheimer's disease. J Neuropathol Exptl Neurol 53, 158-164.
31. Lee VM-Y, Balin BJ, Otvos LJ Jr, Trojanowski JQ (1991) A68: A major subunit of paired helical filaments and derivatized forms of normal tau. Science 251, 675-678.
32. Wischik CM, Edwards PC, Lai RYK, Gertz H-J, Xuereb JH, Paykel ES, Brayne C, Huppert FA, Mukaetova-Ladinska EB, R. M, Roth M, Harrington CR (1995) Quantitative analysis of tau protein in paired helical filament preparations: Implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease. Neurobiol Aging 16, 409-431.
33. Lai RYK, Harrington CR, Wischik CM (2016) Absence of a role for phosphorylation in the tau pathology of Alzheimer's disease. Biomolecules 6, 19.
34. Iqbal K, Liu F, Gong C-X (2014) Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles. Biochem Pharmacol 88, 631-639.
35. Wischik CM, Storey JMD, Wischik DJ, Harrington CR (2016) Inhibition of tau aggregation as a basis for treatment and prevention of Alzheimer's disease. In Developing Therapeutics for Alzheimer's Disease, Wolfe MS, ed. Academic Press, Boston, pp. 385-436.
36. Terman A, Gustafsson B, Brunk UT (2006) Mitochondrial damage and intralysosomal degradation in cellular aging. Mol Aspects Med 27, 471-482.
37. Ihara Y, Morishima-Kawashima M, Nixon R (2012) The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease. Cold Spring Harbor Persp Med 2, a006361.
38. Schultz ML, Tecedor L, Chang M, Davidson BL (2011) Clarifying lysosomal storage diseases. Trends Neurosci 34, 401-410.
39. Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ, Crowther RA, Ghetti B, Goedert M, Scheres SHW (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 547, 185-190.
40. Al-Hilaly YK, Pollack SJ, Vadukul D, Citossi F, Rickard JE, Simpson M, Storey JMD, Harrington CR, Wischik CM, Serpell LC (2017) Alzheimer's disease-like paired helical filament assembly from truncated tau protein is independent of disulphide cross-linking. J Mol Biol 429, 3650-3665.
41. Lumkwana D, du Toit A, Kinnear C, Loos B (2017) Autophagic flux control in neurodegeneration: Progress and precision targeting-Where do we stand? Prog Neurobiol 153, 64-85.
42. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA, Yu WH, Duff KE (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8, 609-622.
43. Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jové M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M (2014) Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet 23, 3716-3732.
44. May JM, Qu Z-c, Cobb CE (2004) Reduction and uptake of methylene blue by human erythrocytes. Am J Physiol - Cell Physiol 286, C1390-C1398.
45. Atamna H, Atamna W, Al-Eyd G, Shanower G, Dhahbi JM (2015) Combined activation of the energy and cellulardefense pathways may explain the potent anti-senescence activity of methylene blue. Redox Biol 6, 426-435.
46. Mansouri A, Lurie AA (1993) Concise review: Methemoglobinemia. Am J Hematol 42, 7-12.
47. Boyce WH, McKinney WM, Long TT, Drach GW (1967) Oral administration of methylene blue to patients with renal calculi. J Urol 97, 783-789.
48. Naylor GJ, Martin B, Hopwood SE, Watson Y (1986) A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry 21, 915-920.
49. Wein AJ, Benson GS, Raezer DM, Mulholland SG (1976) Oral methylene blue and the dissolution of renal calculi. J Urol 116, 140-141.
50. Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JMD, Kook KA, Harrington CR (2015) Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 44, 705-720.
51. Baddeley TC, McCaffrey J, Storey JMD, Cheung JKS, Melis V, Horsley D, Harrington CR, Wischik CM (2015) Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J Pharmacol Exp Therapeutics 352, 110-118.
52. Murthy ASN, Reddy KS (1984) Cyclic-voltammetric studies of some phenothiazine dyes. J Chem Soc Faraday Trans 1 Phys Chem Condensed Phases 80, 2745-2750.
53. Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JMD, Harrington CR, Wischik CM (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873-2884.
54. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New Engl J Med 370, 311-321.
55. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mildto-moderate Alzheimer's disease. New Engl J Med 370, 322-333.
56. Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Reidel G, Storey JMD, Harrington CR, Wischik CM (2018) Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer's disease: cohort analysis as modified primary outcome in a phase 3 clinical trial. J Alzheimers Dis 61, 635-657.
57. Murray AD, Staff RT, Shenkin SD, Deary IJ, Starr JM, Whalley LJ (2005) Brain white matter hyperintensities: Relative importance of vascular risk factors in nondemented elderly people. Radiology 237, 251-257.
58. Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC, for the Alzheimer's Disease Neuroimaging Initiative (2013) Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration. Neurology 80, 648-654.
59. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32, 1207-1218.
60. Lewis DA, Campbell MJ, Terry RD, Morrison JH (1987) Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: A quantitative study of visual and auditory cortices. J Neurosci 7, 1799-1808.
61. Arriagada PW, Growdon JH, Hedley-White ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
62. Bancher C, Braak H, Fischer P, Jellinger K (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease. Neurosci Lett 162, 179-182.
63. Bancher C, Jellinger K, Lassmann H, Fischer P, Leblhuber F (1996) Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci 246, 137-146.
64. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34, 457-468.
65. Duyckaerts C, Bennecib M, Grignon Y, Uchihara T, He Y, Piette F, Hauw J-J (1997) Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 18, 267-273.
66. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H, Lipton RB (1999) Memory and mental status correlates of modified Braak staging. Neurobiol Aging 20, 573-579.
67. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang M-R, Trojanowski JQ, Lee VM-Y, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang M-K, Aoki I, Ito H, Higuchi M (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108.
68. Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM (2000) Staging of cytoskeletal and β-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 157, 623-636.
69. Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Harada R, Yates P, Pejoska S, Kudo Y, Masters CL, Yanai K, Rowe CC, Villemagne VL (2014) Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using F-18-THK5105 PET. Brain 137, 1762-1771.
70. Wilcock GK, Esiri MM (1982) Plaques, tangles and dementia: A quantitative study. J Neurol Sci 56, 343-356.
71. Schmitz TW, Spreng RN (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun 7, 13249.
72. Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, Schicha H, Heiss W-D, Ebmeier K (2002) Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 43, 21-26.
73. Matsuda H (2007) Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med 48, 1289-1300.
74. Bradley KM, O'Sullivan VT, Soper NDW, Nagy Z, King EM-F, Smith AD, Shepstone BJ (2002) Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 125, 1772-1781.
75. Jobst KA, Smith AD, Barker CS, Wear A, King EM, Smith A, Anslow PA, Molyneux AJ, Shepstone BJ, Soper N, Holmes KA, Robinson JR, Hope RA, Oppenheimer C, Brockbank K, McDonald B (1992) Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 55, 190-194.
76. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 36, 811-822.
77. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (2015) Tau imaging: Early progress and future directions. Lancet Neurol 14, 114-124.
78. Schöll M, Almkvist O, Axelman K, Stefanova E, Wall A, Westman E, Långström B, Lannfelt L, Graff C, Nordberg A (2011) Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol Aging 32, 1388-1399.
79. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O'Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 139, 1551-1567.
80. Schöll M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD, Jagust WJ (2016) PET Imaging of tau deposition in the aging human brain. Neuron 89, 971-982.
81. Gertz H-J, Xuereb JH, Huppert FA, Brayne C, Kuüger H, McGee MA, Paykel ES, Harrington CR, Mukaetova-Ladinska EB, O'Connor DW, Wischik CM (1996) The relationship between clinical dementia and neuropathological staging (Braak) in a very elderly community sample. Eur Arch Psychiatry Clin Neurosci 246, 132-136.
82. Ohm TG, Müller H, Braak H, Bohl J (1995) Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 64, 209-217.
83. Prince M, Wimo A, Guerchet M, Ali G-C, WuY-T, Prina M, Alzheimer's Disease International (2015) World Alzheimer Report 2015: The global impact of dementia, an analysis of prevalence, incidence, cost and trends. Alzheimer's Disease International, London.